First Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care, supported by Helsinn, awarded to Dr. Sarah A. Buckley, MD, University of Washington

6 June 2017

Helsinn Group signs Exclusive Agreement with Purdue Pharma (Canada) for the Distribution and Licensing Rights of Aloxi® (palonosetron hydrochloride) in Canada

6 June 2017

Helsinn Group and MEI Pharma Report Correlation between Mutations in DNA Methylation Pathway and Clinical Response in Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

5 June 2017

Giampiero Roncoroni (Zambon SA) nel comitato della VIPS

29 May 2017

Helsinn appoints Eric Cornut to Board of Directors

18 May 2017

Rivopharm announces the acquisition of SANOSWISS UAB

12 April 2017

First New Chemical Entity (NCE) approved for PD patients with motor fluctuations in the U.S.A. in over a decade

24 March 2017

Helsinn announces a collaboration with Lyfebulb

22 March 2017

Helsinn Advanced Synthesis announces new investment

21 February 2017

Intervista a Giorgio Calderari, Helsinn Group General Manager, HC&LS Review Switzerland

20 February 2017